-
Je něco špatně v tomto záznamu ?
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT
JC. Hernández-Boluda, DJ. Eikema, L. Koster, N. Kröger, M. Robin, M. de Witte, J. Finke, MC. Finazzi, A. Broers, L. Raida, N. Schaap, P. Chiusolo, M. Verbeek, CLE. Hazenberg, K. Halaburda, A. Kulagin, H. Labussière-Wallet, T. Gedde-Dahl, W....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Freely Accessible Science Journals
od 1997 do Před 1 rokem
ProQuest Central
od 1997-01-01 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
Health & Medicine (ProQuest)
od 1997-01-01 do Před 1 rokem
- MeSH
- chronická nemoc MeSH
- homologní transplantace škodlivé účinky MeSH
- lidé MeSH
- nádory * komplikace MeSH
- nemoc štěpu proti hostiteli * etiologie MeSH
- primární myelofibróza * genetika terapie komplikace MeSH
- příprava pacienta k transplantaci škodlivé účinky MeSH
- recidiva MeSH
- retrospektivní studie MeSH
- transplantace hematopoetických kmenových buněk * škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Allogeneic hematopoietic cell transplantation (allo-HCT) is curative for myelofibrosis (MF) but assessing risk-benefit in individual patients is challenging. This complexity is amplified in CALR-mutated MF patients, as they live longer with conventional treatments compared to other molecular subtypes. We analyzed outcomes of 346 CALR-mutated MF patients who underwent allo-HCT in 123 EBMT centers between 2005 and 2019. After a median follow-up of 40 months, the estimated overall survival (OS) rates at 1, 3, and 5 years were 81%, 71%, and 63%, respectively. Patients receiving busulfan-containing regimens achieved a 5-year OS rate of 71%. Non-relapse mortality (NRM) at 1, 3, and 5 years was 16%, 22%, and 26%, respectively, while the incidence of relapse/progression was 11%, 15%, and 17%, respectively. Multivariate analysis showed that older age correlated with worse OS, while primary MF and HLA mismatched transplants had a near-to-significant trend to decreased OS. Comparative analysis between CALR- and JAK2-mutated MF patients adjusting for confounding factors revealed better OS, lower NRM, lower relapse, and improved graft-versus-host disease-free and relapse-free survival (GRFS) in CALR-mutated patients. These findings confirm the improved prognosis associated with CALR mutation in allo-HCT and support molecular profiling in prognostic scoring systems to predict OS after transplantation in MF.
1st State Pavlov Medical University of St Petersburg St Petersburg Russian Federation
BMT Unit Internal Medicine 1 Medical University of Vienna Vienna Austria
Central Clinical Hospital The Medical University of Warsaw Warsaw Poland
Centre Hospitalier Lyon Sud Lyon France
CHU de Lille Univ Lille INSERM U1286 Infinite 59000 Lille France
EBMT Leiden Study Unit Leiden the Netherlands
EBMT Statistical Unit Leiden the Netherlands
Erasmus MC Cancer Institute Rotterdam the Netherlands
Hematology Department Federico 2 University of Naples Naples Italy
Hôpital Saint Louis APHP Université de Paris Cité Paris France
Hospital Clínico Universitario INCLIVA University of Valencia Valencia Spain
Institute of Hematology and Transfusion Medicine Warsaw Poland
Maria Skłodowska Curie National Research Institute of Oncology Gliwice Poland
Olomouc University Hospital Olomouc Czech Republic
Radboud University Medical Centre Nijmegen the Netherlands
University College London Hospitals NHS Trust London UK
University Hospital Eppendorf Hamburg Germany
University Medical Center Groningen University of Groningen Groningen the Netherlands
University Medical Center Utrecht the Netherlands
University of Freiburg and Medical Faculty Freiburg Germany
University of Milan and ASST Papa Giovanni XXIII Bergamo Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000491
- 003
- CZ-PrNML
- 005
- 20240213093220.0
- 007
- ta
- 008
- 240109s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41409-023-02094-1 $2 doi
- 035 __
- $a (PubMed)37679647
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Hernández-Boluda, Juan Carlos $u Hospital Clínico Universitario-INCLIVA, University of Valencia, Valencia, Spain. hernandez_jca@gva.es $1 https://orcid.org/0000000242893113
- 245 10
- $a Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT / $c JC. Hernández-Boluda, DJ. Eikema, L. Koster, N. Kröger, M. Robin, M. de Witte, J. Finke, MC. Finazzi, A. Broers, L. Raida, N. Schaap, P. Chiusolo, M. Verbeek, CLE. Hazenberg, K. Halaburda, A. Kulagin, H. Labussière-Wallet, T. Gedde-Dahl, W. Rabitsch, K. Raj, J. Drozd-Sokolowska, G. Battipaglia, N. Polverelli, T. Czerw, I. Yakoub-Agha, DP. McLornan
- 520 9_
- $a Allogeneic hematopoietic cell transplantation (allo-HCT) is curative for myelofibrosis (MF) but assessing risk-benefit in individual patients is challenging. This complexity is amplified in CALR-mutated MF patients, as they live longer with conventional treatments compared to other molecular subtypes. We analyzed outcomes of 346 CALR-mutated MF patients who underwent allo-HCT in 123 EBMT centers between 2005 and 2019. After a median follow-up of 40 months, the estimated overall survival (OS) rates at 1, 3, and 5 years were 81%, 71%, and 63%, respectively. Patients receiving busulfan-containing regimens achieved a 5-year OS rate of 71%. Non-relapse mortality (NRM) at 1, 3, and 5 years was 16%, 22%, and 26%, respectively, while the incidence of relapse/progression was 11%, 15%, and 17%, respectively. Multivariate analysis showed that older age correlated with worse OS, while primary MF and HLA mismatched transplants had a near-to-significant trend to decreased OS. Comparative analysis between CALR- and JAK2-mutated MF patients adjusting for confounding factors revealed better OS, lower NRM, lower relapse, and improved graft-versus-host disease-free and relapse-free survival (GRFS) in CALR-mutated patients. These findings confirm the improved prognosis associated with CALR mutation in allo-HCT and support molecular profiling in prognostic scoring systems to predict OS after transplantation in MF.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a primární myelofibróza $x genetika $x terapie $x komplikace $7 D055728
- 650 _2
- $a homologní transplantace $x škodlivé účinky $7 D014184
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
- 650 12
- $a nádory $x komplikace $7 D009369
- 650 _2
- $a chronická nemoc $7 D002908
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a příprava pacienta k transplantaci $x škodlivé účinky $7 D019172
- 650 12
- $a nemoc štěpu proti hostiteli $x etiologie $7 D006086
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Eikema, Diderik-Jan $u EBMT Statistical Unit, Leiden, the Netherlands
- 700 1_
- $a Koster, Linda $u EBMT Leiden Study Unit, Leiden, the Netherlands
- 700 1_
- $a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany $1 https://orcid.org/0000000151039966
- 700 1_
- $a Robin, Marie $u Hôpital Saint-Louis, APHP, Université de Paris Cité, Paris, France $1 https://orcid.org/0000000313889876
- 700 1_
- $a de Witte, Moniek $u University Medical Center, Utrecht, the Netherlands
- 700 1_
- $a Finke, Jürgen $u University of Freiburg and Medical Faculty, Freiburg, Germany $1 https://orcid.org/0000000217995927
- 700 1_
- $a Finazzi, Maria Chiara $u University of Milan and ASST Papa Giovanni XXIII, Bergamo, Italy
- 700 1_
- $a Broers, Annoek $u Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- 700 1_
- $a Raida, Ludek $u Olomouc University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Schaap, Nicolaas $u Radboud University Medical Centre, Nijmegen, the Netherlands
- 700 1_
- $a Chiusolo, Patrizia $u Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Dipartamento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico A, Gemelli IRCCS, Rome, Italy $1 https://orcid.org/0000000213551587
- 700 1_
- $a Verbeek, Mareike $u Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Clinic and Policlinic for Internal Medicine III, Munich, Germany
- 700 1_
- $a Hazenberg, Carin L E $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
- 700 1_
- $a Halaburda, Kazimierz $u Institute of Hematology and Transfusion Medicine, Warsaw, Poland
- 700 1_
- $a Kulagin, Aleksandr $u First State Pavlov Medical University of St. Petersburg, St. Petersburg, Russian Federation $1 https://orcid.org/0000000295894136
- 700 1_
- $a Labussière-Wallet, Hélène $u Centre Hospitalier Lyon Sud, Lyon, France
- 700 1_
- $a Gedde-Dahl, Tobias $u Oslo University Hospital, Hematology dep, Stem cell transplantation and Institute for Clinical Medicine, University of Oslo, Oslo, Norway
- 700 1_
- $a Rabitsch, Werner $u BMT-Unit, Internal Medicine I, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Raj, Kavita $u University College London Hospitals NHS Trust, London, UK $1 https://orcid.org/000000028258354X
- 700 1_
- $a Drozd-Sokolowska, Joanna $u Central Clinical Hospital, The Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000245626264
- 700 1_
- $a Battipaglia, Giorgia $u Hematology Department, Federico II University of Naples, Naples, Italy $1 https://orcid.org/0000000206953879
- 700 1_
- $a Polverelli, Nicola $u Unit of Blood Diseases and Stem Cell Transplant - ASST Spedali Civili - University of Brescia, Brescia, Italy $1 https://orcid.org/0000000162979697
- 700 1_
- $a Czerw, Tomasz $u Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland
- 700 1_
- $a Yakoub-Agha, Ibrahim $u CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000, Lille, France $1 https://orcid.org/0000000345248782
- 700 1_
- $a McLornan, Donal P $u University College London Hospitals NHS Trust, London, UK. donal.mclornan@nhs.net $1 https://orcid.org/000000031224091X
- 773 0_
- $w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 58, č. 12 (2023), s. 1357-1367
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37679647 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213093217 $b ABA008
- 999 __
- $a ok $b bmc $g 2049259 $s 1210185
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 58 $c 12 $d 1357-1367 $e 20230907 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
- LZP __
- $a Pubmed-20240109
